Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.924 EUR -4.28% Market Closed
Market Cap: 155.7m EUR
Have any thoughts about
Innate Pharma SA?
Write Note

Intrinsic Value

IPH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IPH stock under the Base Case scenario is 5.108 EUR. Compared to the current market price of 1.924 EUR, Innate Pharma SA is Undervalued by 62%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IPH Intrinsic Value
5.108 EUR
Undervaluation 62%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Innate Pharma SA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for IPH cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about IPH?
Bearish
Neutral
Bullish

Fundamental Analysis

1.924 EUR
-4.28%
-4.28%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Innate Pharma SA
FR
Biotechnology
Market Cap
155.7m EUR
IPO
Oct 31, 2006
Employees
215
France
Market Cap
155.7m EUR
Industry
Biotechnology
IPO
Oct 31, 2006
Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Innate Pharma SA

Provide an overview of the primary business activities
of Innate Pharma SA.

What unique competitive advantages
does Innate Pharma SA hold over its rivals?

What risks and challenges
does Innate Pharma SA face in the near future?

Has there been any significant insider trading activity
in Innate Pharma SA recently?

Summarize the latest earnings call
of Innate Pharma SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Innate Pharma SA.

Provide P/S
for Innate Pharma SA.

Provide P/E
for Innate Pharma SA.

Provide P/OCF
for Innate Pharma SA.

Provide P/FCFE
for Innate Pharma SA.

Provide P/B
for Innate Pharma SA.

Provide EV/S
for Innate Pharma SA.

Provide EV/GP
for Innate Pharma SA.

Provide EV/EBITDA
for Innate Pharma SA.

Provide EV/EBIT
for Innate Pharma SA.

Provide EV/OCF
for Innate Pharma SA.

Provide EV/FCFF
for Innate Pharma SA.

Provide EV/IC
for Innate Pharma SA.

Show me price targets
for Innate Pharma SA made by professional analysts.

What are the Revenue projections
for Innate Pharma SA?

How accurate were the past Revenue estimates
for Innate Pharma SA?

What are the Net Income projections
for Innate Pharma SA?

How accurate were the past Net Income estimates
for Innate Pharma SA?

What are the EPS projections
for Innate Pharma SA?

How accurate were the past EPS estimates
for Innate Pharma SA?

What are the EBIT projections
for Innate Pharma SA?

How accurate were the past EBIT estimates
for Innate Pharma SA?

Compare the revenue forecasts
for Innate Pharma SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Innate Pharma SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Innate Pharma SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Innate Pharma SA compared to its peers.

Compare the P/E ratios
of Innate Pharma SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Innate Pharma SA with its peers.

Analyze the financial leverage
of Innate Pharma SA compared to its main competitors.

Show all profitability ratios
for Innate Pharma SA.

Provide ROE
for Innate Pharma SA.

Provide ROA
for Innate Pharma SA.

Provide ROIC
for Innate Pharma SA.

Provide ROCE
for Innate Pharma SA.

Provide Gross Margin
for Innate Pharma SA.

Provide Operating Margin
for Innate Pharma SA.

Provide Net Margin
for Innate Pharma SA.

Provide FCF Margin
for Innate Pharma SA.

Show all solvency ratios
for Innate Pharma SA.

Provide D/E Ratio
for Innate Pharma SA.

Provide D/A Ratio
for Innate Pharma SA.

Provide Interest Coverage Ratio
for Innate Pharma SA.

Provide Altman Z-Score Ratio
for Innate Pharma SA.

Provide Quick Ratio
for Innate Pharma SA.

Provide Current Ratio
for Innate Pharma SA.

Provide Cash Ratio
for Innate Pharma SA.

What is the historical Revenue growth
over the last 5 years for Innate Pharma SA?

What is the historical Net Income growth
over the last 5 years for Innate Pharma SA?

What is the current Free Cash Flow
of Innate Pharma SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Innate Pharma SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Innate Pharma SA

Current Assets 111.6m
Cash & Short-Term Investments 91.8m
Receivables 19.8m
Non-Current Assets 39.9m
Long-Term Investments 10.4m
PP&E 5.7m
Intangibles 119k
Other Non-Current Assets 23.7m
Current Liabilities 38.2m
Accounts Payable 15.9m
Short-Term Debt 10.2m
Other Current Liabilities 12.1m
Non-Current Liabilities 84.5m
Long-Term Debt 68.5m
Other Non-Current Liabilities 16m
Efficiency

Earnings Waterfall
Innate Pharma SA

Revenue
24.9m EUR
Cost of Revenue
-3m EUR
Gross Profit
21.9m EUR
Operating Expenses
-60.5m EUR
Operating Income
-38.6m EUR
Other Expenses
4.5m EUR
Net Income
-34.1m EUR

Free Cash Flow Analysis
Innate Pharma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IPH Profitability Score
Profitability Due Diligence

Innate Pharma SA's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Negative 3-Years Revenue Growth
Negative 1-Year Revenue Growth
18/100
Profitability
Score

Innate Pharma SA's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

IPH Solvency Score
Solvency Due Diligence

Innate Pharma SA's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
43/100
Solvency
Score

Innate Pharma SA's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 5.128 EUR with a low forecast of 2.434 EUR and a high forecast of 8.82 EUR.

Lowest
Price Target
2.434 EUR
27% Upside
Average
Price Target
5.128 EUR
167% Upside
Highest
Price Target
8.82 EUR
358% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IPH?

Click here to dive deeper.

Dividends

Innate Pharma SA
does not pay dividends
Shareholder Yield

Current shareholder yield for IPH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IPH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

See Also

Discover More
What is the Intrinsic Value of one IPH stock?

The intrinsic value of one IPH stock under the Base Case scenario is 5.108 EUR.

Is IPH stock undervalued or overvalued?

Compared to the current market price of 1.924 EUR, Innate Pharma SA is Undervalued by 62%.

Back to Top